Pharmacokinetics, Pharmacodynamics and Drug Metabolism, Merck & Co., Incorporated , West Point, Pennsylvania 19486, United States.
Anal Chem. 2014 Sep 2;86(17):8776-84. doi: 10.1021/ac5019827. Epub 2014 Aug 14.
Quantitation of therapeutic monoclonal antibodies (mAb) using liquid chromatography-tandem mass spectrometry (LC-MS/MS) for pharmacokinetic (PK) studies is becoming an essential complement to traditional antibody-based ligand binding assays (LBA). Here we show an automated method to perform LC-MS/MS-based quantitation, with IgG1 conserved peptides, a heavy isotope labeled mAb internal standard, and anti-human Fc enrichment. All reagents in the method are commercially available with no requirement to develop novel assay-specific reagents. The method met traditional quantitative LC-MS/MS assay analytical characteristics in terms of precision, accuracy, and specificity. The method was applied to the pharmacokinetic study of a mAb dosed in cynomolgus monkey, and the results were compared with the immunoassay data. This methodology has the potential to benefit and accelerate the early biopharmaceutical development process, particularly by enabling PK analysis across species and candidate molecules with minimal method development.
使用液相色谱-串联质谱(LC-MS/MS)定量治疗性单克隆抗体(mAb),用于药代动力学(PK)研究,正在成为传统抗体结合配体分析(LBA)的重要补充。在这里,我们展示了一种自动化方法,用于基于 LC-MS/MS 的定量分析,使用 IgG1 保守肽、重同位素标记的 mAb 内标和抗人 Fc 富集。该方法中的所有试剂均为市售,无需开发新的特定于检测的试剂。该方法在精密度、准确性和特异性方面符合传统的定量 LC-MS/MS 检测分析特性。该方法应用于在食蟹猴中给药的 mAb 的药代动力学研究,并将结果与免疫分析数据进行了比较。该方法有可能促进和加速早期生物制药的开发过程,特别是通过在最小的方法开发工作量下,实现跨物种和候选分子的 PK 分析。